Scholar Rock, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2012-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.scholarrock.com
Clinical Trials
26
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
- Conditions
- Neuromuscular ManifestationsSpinal Muscular AtrophyAnti-myostatinSpinal Muscular Atrophy Type 3SMASpinal Muscular Atrophy Type 2
- Interventions
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT07047144
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
- Conditions
- SMA
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Scholar Rock, Inc.
- Registration Number
- NCT06877689
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
- Conditions
- Overweight and Obesity
- Interventions
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 102
- Registration Number
- NCT06445075
- Locations
- 🇺🇸
ProSciento CRU, Chula Vista, California, United States
🇺🇸AdventHealth Translational Research Institute, Orlando, Florida, United States
🇺🇸Great Lakes Clinical Trials, LLC d/b/a Flourish Research, Chicago, Illinois, United States
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
- Conditions
- Spinal Muscular AtrophySpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2SMANeuromuscular DiseasesMuscular AtrophyAtrophyMuscular Atrophy, SpinalNeuromuscular ManifestationsAnti-myostatin
- Interventions
- First Posted Date
- 2022-11-25
- Last Posted Date
- 2025-05-25
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 238
- Registration Number
- NCT05626855
- Locations
- 🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸UCSD Altman Clinical and Translational Research, La Jolla, California, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
- Conditions
- Spinal Muscular AtrophyNeuromuscular DiseasesAtrophyMuscular Atrophy, SpinalAnti-myostatinSpinal Muscular Atrophy Type 3Spinal Muscular Atrophy Type 2SMAMuscular AtrophyNeuromuscular Manifestations
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Scholar Rock, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT05156320
- Locations
- 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
- Prev
- 1
- 2
- Next